TG Therapeutics, Inc. (TGTX) est une société cotée en bourse dans le Santé secteur, opérant dans le Biotechnologie secteur d'activité. Le siège social de l'entreprise est situé à Morrisville, NY, United States. Le PDG actuel est Michael S. Weiss.
TGTX a date d'introduction en bourse 2010-05-03, 352 employés à temps plein, cotée sur le NASDAQ Capital Marke, une capitalisation boursière de $5.52B.
TG Therapeutics, Inc. is a commercial-stage biopharmaceutical company that develops and commercializes novel treatments targeting B-cell malignancies and autoimmune diseases. The company's lead products include Ublituximab, a monoclonal antibody for non-Hodgkin lymphoma, chronic lymphocytic leukemia, and multiple sclerosis, and Umbralisib, an oral PI3K-delta and CK1-epsilon inhibitor for various lymphomas and leukemia. The pipeline also includes clinical and preclinical candidates such as Cosibelimab (a PD-L1 inhibitor), TG-1701 (a BTK inhibitor), TG-1801 (a bispecific CD47/CD19 antibody), and programs targeting BET, IRAK-4, and GITR. Founded in 1993 and headquartered in New York, TG Therapeutics maintains strategic collaborations and partnerships with leading global pharmaceutical and biotechnology organizations to advance its therapeutic development programs.
